An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.
Epistemonikos ID: 2514ecb7044554bef32979f83ebf24ee4e18b851
First added on: May 12, 2024